We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

57 hedge funds and large institutions have $37.2M invested in Oramed Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 5

53% more capital invested

Capital invested by funds: $24.3M → $37.2M (+$12.9M)

21% more funds holding

Funds holding: 47 → 57 (+10)

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

10.34% more ownership

Funds ownership: 22.46% → 32.81% (+10%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
57
Holders Change
+10
Holders Change %
+21.28%
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
12
Reduced
10
Closed
5
Calls
$19K
Puts
–
Net Calls
+$19K
Net Calls Change
-$126K

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$668K
2
Citadel Advisors
Citadel Advisors
Florida
+$217K
3
HF
HRT Financial
New York
+$119K
4
QC
Quadrature Capital
United Kingdom
+$108K
5
Squarepoint
Squarepoint
New York
+$73.3K

Top Sellers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
-$1.06M
2
BFM
Boothbay Fund Management
New York
-$602K
3
BlackRock
BlackRock
New York
-$50.3K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$28K
5
Bank of America
Bank of America
North Carolina
-$19.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
RFW
26
Redwood Family Wealth
Texas
$65.5K +$59.3K +23,000 New
PCM
27
Prelude Capital Management
New York
$61.6K +$55.7K +21,613 New
PNC Financial Services Group
28
PNC Financial Services Group
Pennsylvania
$60.4K -$5.16K -2,000 -9%
Wealth Enhancement Advisory Services
29
Wealth Enhancement Advisory Services
Minnesota
$56.2K -$1.29K -500 -3%
American Century Companies
30
American Century Companies
Missouri
$55.8K – – –
Morgan Stanley
31
Morgan Stanley
New York
$50.3K +$1.83K +710 +4%
JP Morgan Chase
32
JP Morgan Chase
New York
$49.2K +$44.1K +17,108 +10,064%
SCM
33
Sage Capital Management
New Jersey
$47.7K – – –
LPL Financial
34
LPL Financial
California
$37.6K -$1.03K -400 -3%
AG
35
Algert Global
California
$34K +$31.1K +12,068 New
CAM
36
Close Asset Management
United Kingdom
$33K – – –
AS
37
Altshuler Shaham
Israel
$32K – – –
Mariner
38
Mariner
Kansas
$31.4K – – –
GJIA
39
Glass Jacobson Investment Advisors
Maryland
$30K – – –
SPIA
40
Steward Partners Investment Advisory
New York
$26.4K +$1.14K +440 +5%
Barclays
41
Barclays
United Kingdom
$19.7K -$16.2K -6,281 -48%
Osaic Holdings
42
Osaic Holdings
Arizona
$12.3K – – –
NEWAS
43
N.E.W. Advisory Services
Wisconsin
$9.12K +$8.25K +3,200 New
HNB
44
Huntington National Bank
Ohio
$8.56K – – –
PFO
45
Pioneer Family Office
Florida
$8.55K +$7.74K +3,000 New
UBS Group
46
UBS Group
Switzerland
$7.34K +$5.72K +2,218 +621%
MCM
47
MAI Capital Management
Ohio
$5.86K – – –
Northwestern Mutual Wealth Management
48
Northwestern Mutual Wealth Management
Wisconsin
$4.86K +$338 +131 +8%
SS
49
SBI Securities
Japan
$4.53K – – –
Simplex Trading
50
Simplex Trading
Illinois
$3.26K +$2.95K +1,145 New
1
2
3

ORMP Hedge Fund Activity: Q4 2025 in Review

57 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2025, worth a combined $37.2M — up 53% from $24.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ORMP positions and 5 closed out — a net gain of 10 holders — while 12 added to existing stakes and 10 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $668K. The largest seller was Murchinson, cutting an estimated $1.06M.

  • 57 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2025, up from 47 in Q3 2025.
  • Funds reported $37.2M of Oramed Pharmaceuticals stock for Q4 2025, up 53% quarter-over-quarter.
  • 15 funds opened new Oramed Pharmaceuticals positions in Q4 2025 and 5 closed out, a net change of +10 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2025 was Marshall Wace, an estimated $668K added.
  • The largest Oramed Pharmaceuticals seller in Q4 2025 was Murchinson, an estimated $1.06M sold.

Based on aggregated 13F filings for Q4 2025.